Advertisement

Intensive Chemotherapy for Acute Lymphoblastic Leukaemia in Adults

  • A. Z. S. Rohatiner
  • R. Bassan
  • R. Battista
  • M. J. Barnett
  • W. Gregory
  • J. Lim
  • J. Amess
  • A. Oza
  • T. Barbui
  • M. Horton
  • T. Chisesi
  • T. A. Lister
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

High-dose cytosine arabinoside (HD Ara-C) has been shown to induce complete remission in acute lymphoblastic leukaemia (ALL) which is refractory to, or which has recurred following conventional therapy [1–5]. This study was undertaken to determine whether the incorporation of HD Ara-C at a dose of 2 g/m2 twice daily for 6 days into the treatment previously used at St. Bartholomew’s Hospital (OPAL) [6] would improve the prognosis of adults with ALL.

Keywords

Acute Lymphoblastic Leukaemia Acute Leukaemia Cytosine Arabinoside Blast Count High Dose Cytosine Arabinoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rudnick SA, Cadman EC, Capizzi RL et al. (1979) High dose cytosine arabinoside ( HDARAC) in refractory acute leukaemia. Cancer 44: 1189–1193PubMedCrossRefGoogle Scholar
  2. 2.
    Herzig RH, Wolff SN, Lazarus HM et al. (1983) High dose cytosine arabinoside therapy for refractory leukaemia. Blood 62: 361–369PubMedGoogle Scholar
  3. 3.
    Rohatiner A, Slevin ML, Dhaliwal HS et al. (1984) High dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 12: 90–93PubMedCrossRefGoogle Scholar
  4. 4.
    Kantarjian HM, Estey EH, Plunkett W et al. (1986) Phase I - I I I clinical and pharmacological studies of high dose cytosine arabinoside in refractory leukaemia. Am J Med 81: 387–394PubMedCrossRefGoogle Scholar
  5. 5.
    de Marsh RW, Wozniak A, McCarley D (1987) Therapy of relapsed acute lymphoblastic leukaemia: a 5 year experience with high dose ara-C. Proc Am Assoc Cancer Res Am Soc Clin Oncol 6:147 (in Proc Am Soc Cl in Oncol)Google Scholar
  6. 6.
    Lister TA, Whitehouse JMA, Beard MEJ et al. (1978) Combination chemotherapy for acute lymphoblastic leukaemia in adults. Br Med J: 199–203Google Scholar
  7. 7.
    Barnett MJ, Greaves MF, Amess JAL et al. (1976) Treatment of acute lymphoblastic leukaemia in adults. Br J Haematol 33: 455–468Google Scholar
  8. 8.
    Bennet JM, Catovsky D, Daniel M-T et al. (1976) Proposals for the classification of the acute leukaemias. Br J Haematol 33: 451–458CrossRefGoogle Scholar
  9. 9.
    Storring RA, McElwain TJ, Janeson B et al. (1977) Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet ii: 837–840CrossRefGoogle Scholar
  10. 10.
    Kaplan ES, Meier P (1958) Non-parametric estimation from incomplete observations. Am Stat Assoc J 53: 457–481CrossRefGoogle Scholar
  11. 11.
    Peto R, Pike MC, Armitage P et al. (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 35: 1–39PubMedCrossRefGoogle Scholar
  12. 12.
    Cox DR (1972) Regression models and lifetables. R Stat Soc [B] 34: 187–220Google Scholar
  13. 13.
    Bitran J (1978) Prognostic value of immunological markers in adults with acute lymphoblastic leukaemia. N Engl J Med 299: 1317PubMedGoogle Scholar
  14. 14.
    Baccarani M, Corbellie G, Amadori S et al. (1982) Adolescent and adult lymphoblastic leukaemia: prognostic features and outcome of therapy. A study of 293 patients. Blood 60: 677–684PubMedGoogle Scholar
  15. 15.
    Hoelzer D, Thiel E, Loffler H et al. (1984) Intensified therapy in acute lymphoblastic and acute undifferentiated leukaemia in adults. Blood 64: 38 - 47PubMedGoogle Scholar
  16. 16.
    Marcus RE, Catovsky D, Johnson SA etal. (1986) Adult acute lymphoblastic leukaemia: study of prognostic features and response to treatment over a ten year period. Br J Cancer 53: 175–180PubMedCrossRefGoogle Scholar
  17. 17.
    Hoelzer D, Thiel E, Loffler H etal. (1988) Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukaemia in adults. Blood 71: 123–131PubMedGoogle Scholar
  18. 18.
    Barnett MJ, Richards MA, Ganesan TS et al. (1985) Central nervous system toxicity of high-dose cytosine arabinoside. Semin Oncol 12 (2) [Suppl 3] 223–226PubMedGoogle Scholar
  19. 19.
    Clarkson BD, Ellis S, Little C etal. (1985) Acute lymphoblastic leukaemia in adults. Semin Oncol 12: 160PubMedGoogle Scholar
  20. 20.
    Plunkett W, Liliemark JO, Estey, Keating MJ (1987) Saturation of ara-CTP accumulation during high dose ara-C therapy: pharmacologic rational for intermediate-dose ara-C. Semin Oncol 14: 159PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. Z. S. Rohatiner
    • 1
  • R. Bassan
    • 2
  • R. Battista
    • 3
  • M. J. Barnett
    • 1
  • W. Gregory
    • 1
  • J. Lim
  • J. Amess
    • 4
  • A. Oza
    • 1
  • T. Barbui
    • 2
  • M. Horton
    • 4
  • T. Chisesi
    • 3
  • T. A. Lister
    • 1
  1. 1.ICRF Department of Medical OncologySt. Bartholomew’s, HospitalLondon EC1UK
  2. 2.Hopital RiunitiBergamoItaly
  3. 3.Hopital San BortoloVicenzaItaly
  4. 4.Department of HaematologySt. Bartholomew’s Hospital, HospitalLondon EC1UK

Personalised recommendations